Press Release - May 8, 2018
Heidelberg, Germany, May 8, 2018 – Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today announced that on May 15, 2018, the Company will release its financial results for the quarter ended March 31, 2018. The Company’s management team will host a conference call to discuss the Company’s financial results and recent corporate developments on Tuesday, May 15, 2018 at 8:30 a.m. ET. The call can be accessed by dialing one of the numbers listed below five minutes prior to the start of the call and providing the confirmation code 3326332.
|United States||+1 720-543-0214|
|Germany||+49 (0)89 20303 5709|
|Netherlands||+31 (0) 20 721 9251|
|Denmark||+45 35 15 80 49|
|France||+33 (0)1 76 77 22 74|
|Switzerland||+41 (0)22 567 5729|
|United Kingdom||+44 (0)330 336 9105|
An audio webcast of the conference call can be accessed in the “Events” section on the “Investors & Media” page of the Affimed website at the Webcasts. A replay of the webcast will be available on Affimed’s website shortly after the conclusion of the call and will be archived on the Affimed website for 30 days following the call.
Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK and T cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit www.affimed.com.
Anca Alexandru, Head of Communications, EU IR
Phone: +49 6221 64793341